Jeffrey Meyerhardt, MD, MPH
Enriched profileSenior Physician and Chief Clinical Research Officer, Dana-Farber Cancer Institute; Professor of Medicine, Harvard Medical School · Dana-Farber Cancer Institute
Jeffrey Meyerhardt is Senior Physician and Chief Clinical Research Officer, Dana-Farber Cancer Institute; Professor of Medicine, Harvard Medical School at Dana-Farber Cancer Institute. OpenAlex indexes 1,086 publications with 53,998 citations (h-index 119); ClinicalTrials.gov lists 11 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Medical Oncology profiles in the findmyKOL directory. Clarivate lists Jeffrey Meyerhardt as a Highly Cited Researcher (Cross-Field, 2019, 2023-2024).
Data verified 14 Aug 2026
Overview
Updated 16 Oct 2026
Jeffrey Meyerhardt, MD MPH, is Senior Physician and Chief Clinical Research Officer, Dana-Farber Cancer Institute. The public record shows 1,086 publications with 53,998 citations (h-index 119), centered on Colorectal Cancer Treatments and Studies, Genetic factors in colorectal cancer, Nutrition and Health in Aging. It also documents an investigator role on 11 registered clinical trials, industry payments reported by 3 companies, 5 NIH-funded awards (2003–2026).
- Top research focus: Colorectal Cancer Treatments and Studies
- 11 registered trials on ClinicalTrials.gov
- Open Payments reporting from 3 companies
Generated from the cited public record · current as of 16 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 46 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 411.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 16 Oct 2026
Listed as an investigator on 11 registered studies on ClinicalTrials.gov. The most recent:
- Adaptive Randomization of Aerobic Exercise During Chemotherapy in Colon Cancer
Sponsor: AdventHealth Translational Research Institute
- Physical Activity In Gastrointestinal Cancer
Sponsor: Dana-Farber Cancer Institute
Industry payments
Updated 16 Oct 2026
3 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
- Janssen Scientific Affairs, LLCProgram year20221 payment
- Merck Sharp & Dohme CorporationProgram year20211 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
73.8%Central Nervous System Stimulant47.6%Methylphenidate Hcl100%Part D<11 patientsPhenothiazine26.2%Prochlorperazine Maleate100%Part D<11 patientsMetabolism & gastrointestinal
26.2%Serotonin-3 Receptor Antagonist26.2%Ondansetron Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 16 Oct 2026
5 NIH research awards on record, funded 2003–2026 per NIH RePORTER. The latest:
- Adaptive Randomization of Aerobic Exercise During Chemotherapy in Colon Cancer
Adventhealth Orlando
FY2026$1,229,874U01CA271279
Congress activity
Updated 16 Oct 2026
140 congress contributions (2004–2026) across AACR, ASCO, ASTRO, ESMO, SABCS per OpenAlex. The most recent:
- Abstract 5038: Associations of WCRF/AICR recommendations with survival and chemotherapy outcomes in colon cancer: CALGB/SWOG 80702 (Alliance)
AACR Annual Meeting
AACR2026Co-author - Abstract 7596: Risk factors and prediction models for colorectal cancer in older US individuals.
AACR Annual Meeting
AACR2026Co-author - Lycopene and survival in patients with stage III colon cancer: Findings from CALGB (Alliance)/SWOG 80702.
ASCO Annual Meeting
ASCO2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network
2024 - Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network
2022 - American Cancer Society nutrition and physical activity guideline for cancer survivors
CA A Cancer Journal for Clinicians
2022 - Exercise, Diet, and Weight Management During Cancer Treatment: ASCO Guideline
Journal of Clinical Oncology
2022
Most-cited works
by citation count (OpenAlex)- 01Nutrition and physical activity guidelines for cancer survivors2,026 citations2012
- 02Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology1,756 citations2021
- 03Duration of Adjuvant Chemotherapy for Stage III Colon Cancer1,132 citations2018
- 04
- 05Systemic Therapy for Colorectal Cancer1,052 citations2005
Network
Updated 16 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 16 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/jeffrey-meyerhardt-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/jeffrey-meyerhardt-6974662a5
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
Mentions by others
where others cite or feature them- Other
ascopost.com/videos/2019-gastrointestinal-cancers-symposium/jeffrey-meyerhardt-on-adjuvant-chemotherapy-in-colon-cancer
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗ - Spotify
open.spotify.com/show/3ZcdgQVGwt0wJesfEKp7G9
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →open.spotify.com ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 16 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →dana-farber.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →dana-farber.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →dana-farber.org ↗
Editorial & leadership roles
journal and society appointments- Co-Director
Colon and Rectal Cancer Center, Dana-Farber Cancer Institute
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →dana-farber.org ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →dana-farber.org ↗
- Project Co-Leader
Gastrointestinal Cancer SPORE, Dana-Farber/Harvard Cancer Center
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →dana-farber.org ↗ - Co-Chair
Alliance for Clinical Trials in Oncology GI Committee (NCI cooperative group)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →dana-farber.org ↗ - Associate Director of Clinical Trials
DFHCC Executive Committee; Member, Center Scientific Council
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dfhcc.harvard.edu ↗ - Contributor to ASCO and American Cancer Society colorectal cancer treatment guidelines; author
NCCN Guidelines Insights: Rectal Cancer
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →jnccn.org ↗
Highly Cited Researcher
Clarivate's annual list, by award category and year- Cross-Field201920232024verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →clarivate.com ↗
Awards & honors
honors on the public record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →dana-farber.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →dana-farber.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →dana-farber.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →dana-farber.org ↗
Secondary affiliations
appointments beyond the home institution- Dana-Farber/Harvard Cancer Center (DFHCC)
Member, Cancer Epidemiology research program; Member, Gastrointestinal Malignancies research program
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dfhcc.harvard.edu ↗ - Brigham and Women's Hospital
Medical Oncology (Boston/Chestnut Hill, MA)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →physiciandirectory.brighamandwomens.org ↗
Media & interviews
press, podcasts and appearances- Co-host
"How We Treat: Colon and Rectal Cancer" podcast (with Dr. Ronald Bleday)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →open.spotify.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.net ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →dailynews.ascopubs.org ↗
- Presenter
"Jeffery Meyerhardt Diet and Lifestyle" (Fight CRC conference slide presentation)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →slideshare.net ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Kenneth Anderson, MD
Dana-Farber Cancer Institute
Paul Richardson, MD
Dana-Farber Cancer Institute
Toni Choueiri, MD
Dana-Farber Cancer Institute
Pasi Janne, MD, PhD
Dana-Farber Cancer Institute
Eric Van Cutsem, MD, PhD
University Hospitals Leuven (UZ Leuven)
Josep Tabernero, MD, PhD
Vall d'Hebron Institute of Oncology (VHIO)
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
Charles Fuchs, MD, MPH
Tubulis GmbH